In patients with early-onset myasthenia gravis with anti-acetylcholine receptor antibodies, the presence of titin antibody indicates a 95-100 percent likelihood of an underlying thymoma
See Compliance Statement D
Statement D: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.